Skeletal Muscle Mass Influences Tolerability and Prognosis in Hepatocellular Carcinoma Patients Treated with LenvatinibHaruki Uojima, Wasaburo Koizumi, Makoto Chuma et al.|Liver Cancer|2019Cited by 91
<p>Safety and Efficacy of Lenvatinib Treatment in Child–Pugh A and B Patients with Unresectable Hepatocellular Carcinoma in Clinical Practice: A Multicenter Analysis</p>Katsuaki Ogushi, Shin Maeda, Naohisa Wada et al.|Clinical and Experimental Gastroenterology|2020Cited by 55
Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular CarcinomaMakoto Chuma, Shin Maeda, Haruki Uojima et al.|Cancers|2020Cited by 54
Circulating microRNA‐1246 as a possible biomarker for early tumor recurrence of hepatocellular carcinomaMakoto Chuma, Naoya Sakamoto, Juntaro Matsuzaki et al.|Hepatology Research|2019Cited by 43
Diagnostic Value of Imaging Methods in the Histological Four Grading of Hepatocellular CarcinomaFeiqian Wang, Shin Maeda, Kazushi Numata et al.|Diagnostics|2020Cited by 22